Can-Fite BioPharma rises on plans to initiate cancer drug mid-stage trial

Can Fite Biopharma

09/05/2023 13:53

** U.S.-listed shares of Israel-based Can-Fite BioPharma Ltd
 CANF.N   CANF.TA  rise 2.2% to $2.1 premarket  
    ** Co says it will initiate a mid-stage trial, testing its
experimental drug to treat pancreatic cancer
    ** Study aims to test potential safety and efficacy of the
drug candidate, namodenoson, in patients with pancreatic cancer
who have received at least one previous therapy   
    ** Namodenoson is also being tested in a late-stage study to
treat patients with liver cancer -CANF 
    ** Says the global pancreatic cancer therapeutics market is
estimated to grow to approximately $6.6 bln by 2030, according
to Acumen Research study 
    ** Up to last close, stock down ~67% YTD

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))